信达生物与Spero Therapeutics Inc.共同宣布,双方已就Ibi355(亦称为SP001)达成一项独家授权协议。该候选药物是一款已准备进入二期临床试验阶段的第三代抗CD40L抗体。
信达生物与Spero Therapeutics Inc.共同宣布,双方已就Ibi355(亦称为SP001)达成一项独家授权协议。该候选药物是一款已准备进入二期临床试验阶段的第三代抗CD40L抗体。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.